---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042630"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:50:02.293642+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers

## Summary
- First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.
- Primary target patient population is non-small cell lung cancer (NSCLC).
- Lilly leads clinical development under a U.S. 50/50 co-development and co-commercialization collaboration with Foghorn.
- Preclinical studies showed robust anti-tumor monotherapy activity and favorable tolerability in SMARCA2 mutant xenograft models.

## SEC filing metadata
- accession: 0001628280-24-042630
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/0001628280-24-042630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024042630/fhtx-20241010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042630
- JSON: https://secwatch.observer/filing/0001628280-24-042630.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.